Press Room

Webinar - Heavy Metals determination by UPLC

Start
Thursday, January 29, 2015 - 14:00
End
Thursday, January 29, 2015 - 15:00

Speakers

António Ramos

Analytical Development Group Leader 

Lúcia Volta e Sousa

PhD Student / Analytical Chemist

 

Elemental impurities analysis has a great importance within pharmaceutical realm due to its impact on the quality, safety and efficacy of drug product and substances. These impurities can include catalysts and environmental contaminants that may be present in drug substances, excipients or drug product. For that reason, it is necessary to have a rigid control, during the manufacturing process in order to assure that the final product is within the specification limits described in the USP chapter and recently approved ICH Q3D guideline. There are two procedures acknowledge by USP that can be used to analyze and control these materials, as ICP-MS and ICP-AES. These techniques are expensive and most of the times are not available in every manufacturing sites. According to USP acceptable alternative procedures that meet validation requirements can be used. An alternative Microwave / UPLC / UV-VIS provides a powerful, advantageous and fast solution for heavy metals determination with improvements in terms of time and costs. The breakthrough is the use of microwave based digestion to obtain a universal method that can be applied to any organic matrix. The use of a Quality by Design approach will allow for a better understanding of the method design space and a more effective method development.

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025